Recent studies highlight the promising use of psychedelic therapies for psychiatric disorders, including depression. The persisting clinical effects of psychedelics such as psilocybin are commonly attributed to activation of the serotonin 2A receptor (5-HT2AR) based on its role in the acute hallucinatory effects. However, the active metabolite of psilocybin binds to many serotonin receptor...
should have read "Overall, our research implicates the 5-HT1BR, a nonhallucinogenic serotonin receptor, as a potential mediator of the behavioral and neural effects of psilocybin in mice."The final sentence of the Introduction should have read "Our findings suggest that the 5-HT1BR influences brain-wide neural changes following psilocybin administration and may contribute to its enduring...
ABSTRACT Psychedelic drugs offer a potentially promising avenue for novel therapeutics for the treatment of psychiatric conditions, including for mood and anxiety disorders. Emerging clinical studies have prompted increased preclinical research into mechanisms of action. However, post-acute behavioral outcomes in rodents remain inconsistent and difficult to reproduce across laboratories. To...